SOX2 and breast cancer: Interestingly, ActD was recently shown to specifically downregulate SOX2 expression in breast cancer and glioblastoma, SOX2 being a key regulator of stem cells’ self-renewal capacity, associated with glioblastoma aggressiveness and poor prognosis [76,77].